Muscle Spasm - Pipeline Review, H1 2012

Muscle Spasm – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Muscle Spasm - Pipeline Review, H1 2012', provides an overview of the Muscle Spasm therapeutic pipeline. This report provides information on the therapeutic development for Muscle Spasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Spasm. 'Muscle Spasm - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Muscle Spasm.
- A review of the Muscle Spasm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Muscle Spasm pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Muscle Spasm.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Muscle Spasm pipeline depth and focus of Muscle Spasm therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Muscle Spasm Therapeutic Products under Development, Key Players in Muscle Spasm Therapeutics, Muscle Spasm Pipeline Overview, Muscle Spasm Pipeline, Muscle Spasm Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscle Spasm Overview
Therapeutics Development
An Overview of Pipeline Products for Muscle Spasm
Muscle Spasm Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Muscle Spasm Therapeutics – Products under Development by Companies
Companies Involved in Muscle Spasm Therapeutics Development
Eisai Co., Ltd.
Sanochemia Pharmazeutika AG
Muscle Spasm – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Tolperisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tolperisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E2000 + Diclofenac Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Muscle Spasm Therapeutics – Discontinued Products
Muscle Spasm Therapeutics - Dormant Products
Muscle Spasm – Product Development Milestones
Featured News & Press Releases
May 16, 2011: Watson Launches Generic AMRIX
Dec 01, 1994: Royce laboratories, inc. receives FDA approval for Cyclobenzaprine hydrochloride
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Muscle Spasm, H1 2012
Products under Development for Muscle Spasm – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Eisai Co., Ltd., H1 2012
Sanochemia Pharmazeutika AG, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Muscle Spasm Therapeutics – Discontinued Products
Muscle Spasm Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Muscle Spasm, H1 2012
Products under Development for Muscle Spasm – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012